Aerocrine to secure $31.76 million financing from Novo - MarketLine Financial Deals

Aerocrine to secure $31.76 million financing from Novo

Aerocrine to secure $31.76 million financing from Novo - MarketLine Financial Deals
Aerocrine to secure $31.76 million financing from Novo
Published Sep 16, 2010
3 pages — Published Sep 16, 2010
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Aerocrine AB, a Sweden-based medical technology company, is planning to raise SEK225 million ($31.76 million) through a directed issue of new shares and convertible bonds.

  
Source:
Document ID
MA32889_100921
Country
Ticker
AERO=SE
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Aerocrine to secure $31.76 million financing from Novo" Sep 16, 2010. Alacra Store. Dec 02, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Aerocrine-to-secure-31-76-million-financing-from-Novo-2052-43779>
  
APA:
MarketLine Financial Deals. (2010). Aerocrine to secure $31.76 million financing from Novo Sep 16, 2010. New York, NY: Alacra Store. Retrieved Dec 02, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Aerocrine-to-secure-31-76-million-financing-from-Novo-2052-43779>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.